Patent ID: 11957114
Assignee: MIRIMUS, INC.
Field: Biotechnology (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 5:
6. The method of claim 4, wherein the promoter driving expression of the miRNA-based shRNA is selected from the group consisting of: a tet-inducible, the PolIII human or murine U6 and H1 systems, the cytomegalovirus (CMV) promoter/enhancer, the human β-actin promoter, the glucocorticoid-inducible promoter present in the rat and mouse mammary tumor virus long terminal repeat (MMTV LTR), the long terminal repeat sequences of Moloney murine leukemia virus (MuLV LTR), the SV40 early or late region promoter, the promoter contained in the 3′ long terminal repeat of Rous sarcoma virus (RSV), the herpes simplex virus (HSV) thymidine kinase promoter/enhancer, the herpes simplex virus LAT promoter, polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems, and inducible systems, including Tet promoters.